503583593 11/24/2015 PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3630222

SUBMISSION TYPE:		NEW ASSIGNMENT				
NATURE OF CONVEYANCE:			ASSIGNMENT			
CONVEYING PARTY	DATA					
			Name	Execution Date		
JOHN H. VAN DUZER					01/21/2014	
RALPH MAZITSCHEK					01/21/2014	
RECEIVING PARTY D	ΑΤΑ					
Name:	ACETYLON PHARMACEUTICALS, INC.					
Street Address:	70 FA	70 FARGO STREET				
Internal Address:	SUITE	SUITE 205				
City:	BOST	BOSTON				
State/Country:	MASS	MASSACHUSETTS				
Postal Code:	02210	02210				
	0 Tatala					
PROPERTY NUMBERS Total: 1 Property Type			Number	٦		
		1482				
CORRESPONDENCE	DATA		000 4004			
Fax Number:	ha cant t	• •	300-4001 e-mail address first; if that is un	16	uccessful it will be sent	
			hat is unsuccessful, it will be se			
			004000			
			onpatent@lathropgage.com,ekarna	as	@lathropgage.com,dvincent@	lathropgag
			IROP & GAGE LLP			
			N C. TRINQUE, PH.D., ESQ.			
Address Line 4:		<u>в</u> ОЗ	TON, MASSACHUSETTS 02109			
ATTORNEY DOCKET NUMBER:			572606: ACT-003DV			
NAME OF SUBMITTER:			BRIAN C. TRINQUE, PH.D., ESQ.			
SIGNATURE:			/BRIAN C. TRINQUE/			
DATE SIGNED:			11/24/2015			
Total Attachments: 3						
_	_		signment_11-24-15#page1.tif			
—	_		signment_11-24-15#page2.tif			
source=551707_ACT-00)3_Execut	ted As	signment_11-24-15#page3.tif			

ASSIGNMENT

WHEREAS, we, John H. van Duzer, of Georgetown, Massachusetts, and Ralph Mazitschek of Belmont, Massachusetts have invented

SELECTIVE HDAC1 AND HDAC2 INHIBITORS

U.S. Serial No.: 14/069,741 filed November 1, 2013,

for which we are about to make or have made application for Letters Patent of the United States; and

WHEREAS, ACETYLON PHARMACEUTICALS, INC., having its principal place of business at 70 Fargo Street, Suite 205, Boston, Massachusetts 02210, is desirous of acquiring all rights, title and interests in and to said invention, said applications, and in and to any and all Letters Patent which may be granted for or upon said invention and applications in the United States of America and anywhere in the world.

NOW THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, we, John H. van Duzer and Ralph Mazitschek, have sold, assigned and transferred, and by these presents to sell, assign and transfer unto the said ACETYLON

PHARMACEUTICALS, INC., the full and exclusive right, title and interest, throughout the world, in, to and under the following:

(a) said invention as fully set forth and described in the specification prepared, and executed by us preparatory to obtaining Letters Patent of the United States therefor;

(b) said applications;

(c) any and all refilings, divisions, continuations and continuations-in-part of said applications;

(d) any and all Letters Patent of the United States of America which may issue from said applications, refilings, divisions, continuations and continuations-in-part;

(c) any and all reissues and reexaminations of said Letters Patent of the United States of America;

Page 1 of 3

PATENT REEL: 037130 FRAME: 0914

(f) any and all applications for Letters Patent upon said invention which may hereafter be filed in any and all countries foreign to the United States of America;

(g) any and all refilings, divisions and continuations of said foreign-filed applications;

(h) all claims, causes of action and damages for past infringement, if any, of said application;

(i) any and all Letters Patent of countries foreign to the United States of America which may issue from the said foreign-filed applications, refilings, divisions and continuations; and

(j) any and all extensions of, and additions to, said Letters Patent of countries foreign to the United States of America.

We, John H. van Duzer and Ralph Mazitschek, further agree that upon request we will provide promptly all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ACETYLON PHARMACEUTICALS, INC., or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

ALL of the above shall be held and enjoyed by said ACETYLON

PHARMACEUTICALS, INC., for its own use and benefit, and for its successors, legal representatives and assigns, to the full end of the term for which said Letters Patent may be granted, and we do hereby authorize and request the Commissioner of Patents and Trademarks to issue the said Letters Patent in accordance with this Assignment.

Page 2 of 3

PATENT REEL: 037130 FRAME: 0915

Attorney Docket No: 551707 (ACT-003)

This Assignment to have effect as of the filing date of November 1, 20)3.

21- JAN- 2014

Jøhn H. van Duzer

Signed in my presence and acknowledged to be an assignment of the application herein above referred to:

WITNESS

et 100 Pharmacehicds ned At (City/State)

b Ju Nessvallo ak Name Signature

21-2014 $Ot \cdot$

Date

<u>O(/ 2/ / 14</u> Date:

and the second s

Raiph Mazitschek

Signed in my presence and acknowledged to be an assignment of the application herein above referred to:

WITNESS <u>+ Cety on Pharmaeertral</u> gned At (Clty/State) <u>Abdu Nessvalla Gr</u> Name Signature 01-<u> 2106 / K</u>

Date

Page 3 of 3

20923566v1

PATENT REEL: 037130 FRAME: 0916

RECORDED: 11/24/2015